Recombinant
RabMAb

Recombinant Anti-CD19 antibody [EPR5906] (HRP) (ab195896)

Overview

  • Product name

    Anti-CD19 antibody [EPR5906] (HRP)
    See all CD19 primary antibodies
  • Description

    Rabbit monoclonal [EPR5906] to CD19 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: IHC-P, WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human CD19 aa 300 to the C-terminus.

  • Positive control

    • WB: Ramos whole cell lysate. IHC-P: Normal human tonsil tissue.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab195896 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

ab199507 - Rabbit monoclonal IgG (HRP), is suitable for use an as isotype control with this antibody.

 

WB 1/5000. Detects a band of approximately 85 kDa (predicted molecular weight: 61 kDa).

Target

  • Function

    Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
  • Involvement in disease

    Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
  • Sequence similarities

    Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
  • Post-translational
    modifications

    Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • Antibody deficiency due to defect in CD19 antibody
    • Antibody deficiency due to defect in CD19, included antibody
    • AW495831 antibody
    • B lymphocyte antigen CD19 antibody
    • B lymphocyte surface antigen B4 antibody
    • B-lymphocyte antigen CD19 antibody
    • B-lymphocyte surface antigen B4 antibody
    • B4 antibody
    • CD19 antibody
    • CD19 antigen antibody
    • CD19 molecule antibody
    • Cd19 protein antibody
    • CD19_HUMAN antibody
    • CVID3 antibody
    • Differentiation antigen CD19 antibody
    • Leu 12 antibody
    • Leu-12 antibody
    • Leu12 antibody
    • MGC109570 antibody
    • MGC12802 antibody
    • T-cell surface antigen Leu-12 antibody
    see all

Images

  • IHC image of CD19 staining in a section of formalin-fixed paraffin-embedded normal human tonsil*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab195896, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • Anti-CD19 antibody [EPR5906] (HRP) (ab195896) at 1/5000 dilution + Ramos (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 61 kDa
    Observed band size: 85 kDa
    why is the actual band size different from the predicted?


    Exposure time: 3 minutes


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab195896 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab195896 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab195896.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up